A portable system for processing donated whole blood into high quality components without centrifugation.

BACKGROUND: The use of centrifugation-based approaches for processing donated blood into components is routine in the industrialized world, as disparate storage conditions require the rapid separation of 'whole blood' into distinct red blood cell (RBC), platelet, and plasma products. However, the logistical complications and potential cellular damage associated with centrifugation/apheresis manufacturing of blood products are well documented. The objective of this study was to evaluate a proof-of-concept system for whole blood processing, which does not employ electromechanical parts, is easily portable, and can be operated immediately after donation with minimal human labor. METHODS AND FINDINGS: In a split-unit study (n = 6), full (~500mL) units of freshly-donated whole blood were divided, with one half processed by conventional centrifugation techniques and the other with the new blood separation system. Each of these processes took 2-3 hours to complete and were performed in parallel. Blood products generated by the two approaches were compared using an extensive panel of cellular and plasma quality metrics. Comparison of nearly all RBC parameters showed no significant differences between the two approaches, although the portable system generated RBC units with a slight but statistically significant improvement in 2,3-diphosphoglyceric acid concentration (p < 0.05). More notably, several markers of platelet damage were significantly and meaningfully higher in products generated with conventional centrifugation: the increase in platelet activation (assessed via P-selectin expression in platelets before and after blood processing) was nearly 4-fold higher for platelet units produced via centrifugation, and the release of pro-inflammatory mediators (soluble CD40-ligand, thromboxane B2) was significantly higher for centrifuged platelets as well (p < 0.01). CONCLUSION: This study demonstrated that a simple, passive system for separating donated blood into components may be a viable alternative to centrifugation-particularly for applications in remote or resource-limited settings, or for patients requiring highly functional platelet product.

Viability of cryopreserved parathyroid tissue: when is continued storage versus disposal indicated?

BACKGROUND: Parathyroid cryopreservation is used for potential autografting in patients who are rendered hypocalcemic following surgery. Cryopreservation employs multiple resources and carries a significant cost for processing and storage of tissue. Importantly, the length of time that parathyroid tissue remains functional after cryopreservation is not known. The goal of our study was to assess ex-vivo viability of parathyroid tissue in relation to the length of time in storage. We sought to define the appropriate time frame for tissue utilization and disposal to assist with long-term surgical planning. METHODS: From 1991 to 2006, 501 parathyroid specimens from 149 patients were cryopreserved at -80 degrees C according to standardized techniques. A single trained technician assessed viability, using a hemacytometer to count viable (clear cell) and nonviable (blue cell) tissue. Univariate analysis was performed to correlate length of preservation, diagnosis with viability. RESULTS: We evaluated 106 random parathyroid specimens. Samples were divided into two groups: those stored>24 months and those stored24 months (p<0.001). CONCLUSIONS: Viability of cryopreserved parathyroid cells is associated with duration of storage. Parathyroids preserved for greater than 24 months are unlikely to be viable. It seems reasonable to limit parathyroid cryopreservation to 24 months when frozen at -80 degrees C. Further studies are needed to optimize the process of cryopreservation to enhance cell viability.